Instead, ACE inhibitors may be considered for use in individuals with NAFLD due to the multifactorial benefits they present where aside from regulation of blood pressure (45), ACE inhibitors have been found to reduce decompensation (46), hepatic fibrosis (47), and steatosis (48) in NAFLD and may also provide protection against CKD (49). Here, ACE is linked to metabolic dysfunction-associated steatotic liver disease.